What is BioLamina?
BioLamina is a biotechnology company based in Sweden that specializes in the creation of full-length human recombinant laminins. These products serve as a biologically relevant matrix for cell culture applications, enhancing cellular functionality and supporting both 2D and 3D cell culture systems. The company targets researchers and clinicians, providing offerings designed to meet stringent regulatory requirements, thereby ensuring clinical compliance and reproducible outcomes. BioLamina's focus on improving cell performance and differentiation aims to drive advancements in the fields of cell therapy and regenerative medicine.
How much funding has BioLamina raised?
BioLamina has raised a total of $18.2M across 1 funding round:
Other Financing Round
$18.2M
Other Financing Round (2023): $18.2M with participation from Lauxera Capital Partners
Key Investors in BioLamina
Lauxera Capital Partners
Lauxera Capital Partners is an investment fund focused on growth companies in the Healthtech sector, aiming to enhance efficiency and reduce costs through strategic investments in early profitability stage businesses.
What's next for BioLamina?
The recent major strategic investment positions BioLamina for accelerated growth and further innovation in the competitive biotechnology landscape. This capital will likely be directed towards expanding research and development initiatives, scaling production capabilities, and strengthening market penetration. The company's focus on clinical compliance and reproducible results suggests a strategic emphasis on serving the demanding needs of the cell therapy and regenerative medicine sectors, potentially paving the way for broader adoption of their advanced cell culture matrices.
See full BioLamina company page
